Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the…
Read more Novartis Nears Deal to Acquire Avidity BiosciencesIsomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and…
Read more Isomorphic inks deals with Eli Lilly and Novartis for drug discovery | TechCrunchTwo weeks ago, bluebird bio secured Food and Drug Administration approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in…
Read more Bluebird Bio Stock Is in Free FallBy Adria Calatayud Novartis raised its full-year earnings guidance for the third time this year after it reported higher net profit and sales for the third quarter, boosted…
Read more Novartis Raises 2023 ViewBy Adria Calatayud Novartis said an interim analysis from a phase 3 trial to evaluate its investigational iptacopan drug in patients with kidney disease nephropathy achieved positive results,…
Read more Novartis Says Kidney Drug Phase 3 Trial Reaches Positive Interim ResultBy Adria Calatayud Novartis said the planned spinoff of its Sandoz generic pharmaceuticals and biosimilars business is expected to occur on or around Oct. 4. The Swiss pharmaceutical…
Read more Novartis Sets Sandoz Spinoff Date for Oct. 4We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. Summary Summary U.S Europe Asia FX Rates Futures ETFs Crypto…
Read more Bank of America, Morgan Stanley, Lockheed, Masimo, Novartis, and More Stock Market Movers
